These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33008789)

  • 1. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
    Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
    Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
    Tural D; Selçukbiricik F; Ölmez ÖF; Sümbül AT; Erman M; Coşkun HŞ; Artaç M; Kılıçkap S
    Int J Clin Oncol; 2022 Mar; 27(3):585-591. PubMed ID: 34762201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Drakaki A; Powles T; Bamias A; Martin-Liberal J; Shin SJ; Friedlander T; Tosi D; Park C; Gomez-Roca C; Joly Lobbedez F; Castellano D; Morales-Barrera R; Moreno-Candilejo I; Fléchon A; Yuen K; Rishipathak D; DuPree K; Young F; Michielin F; Shemesh CS; Steinberg EE; Williams P; Lee JL
    Clin Cancer Res; 2023 Nov; 29(21):4373-4384. PubMed ID: 37651261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
    Cathomas R; Schardt J; Pless M; Llado A; Mach N; Riklin C; Haefeli J; Fear S; Stenner F
    Swiss Med Wkly; 2020 May; 150():w20223. PubMed ID: 32399958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
    Tural D; Ölmez ÖF; Sümbül AT; Özhan N; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S; Artaç M
    Int J Clin Oncol; 2021 Aug; 26(8):1506-1513. PubMed ID: 34023933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
    van der Heijden MS; Loriot Y; Durán I; Ravaud A; Retz M; Vogelzang NJ; Nelson B; Wang J; Shen X; Powles T
    Eur Urol; 2021 Jul; 80(1):7-11. PubMed ID: 33902955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
    Perez-Gracia JL; Loriot Y; Rosenberg JE; Powles T; Necchi A; Hussain SA; Morales-Barrera R; Retz MM; Niegisch G; Durán I; Théodore C; Grande E; Shen X; Wang J; Nelson B; Derleth CL; van der Heijden MS
    Eur Urol; 2018 Mar; 73(3):462-468. PubMed ID: 29273410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
    Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
    JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
    Díaz Acedo R; Galvan Banqueri M; Artacho Criado S; Fernández Parra EM; Jiménez Galán R; Gago Sánchez AI; Marín Pozo JF; Martínez Bautista MJ
    Int J Clin Pharm; 2024 Apr; 46(2):382-389. PubMed ID: 38112892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
    Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
    Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
    Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA
    Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
    Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
    Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
    Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
    Eur Urol Oncol; 2024 Aug; 7(4):933-943. PubMed ID: 38105142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.